Your browser doesn't support javascript.
loading
Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022.
García-Sempere, Aníbal; Giménez, Estela; Vanaclocha, Hermelinda; Limón, Ramón; Peiró, Salvador; Navarro, David.
Afiliação
  • García-Sempere A; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), València, Spain; Chronicity, Primary Care, and Health Promotion Research Network (RICAPPS), València, Spain. Electronic address: garcia_ani@gva
  • Giménez E; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, València, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Spain.
  • Vanaclocha H; General Directorate of Public Health, Department of Health, Valencian Government, València, Spain.
  • Limón R; General Directorate of Healthcare, Department of Health, Valencian Government, València, Spain.
  • Peiró S; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), València, Spain; Chronicity, Primary Care, and Health Promotion Research Network (RICAPPS), València, Spain.
  • Navarro D; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, València, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Spain; Department of Microbiology, School of Medicine, University of Valencia, València, Spain.
Gac Sanit ; 37: 102312, 2023.
Article em En | MEDLINE | ID: mdl-37331154
ABSTRACT

OBJECTIVE:

To estimate the seroprevalence of SARS-CoV-2 antibodies in the Valencian Community (Spain) in October 2022, when BA.5 was the predominant variant.

METHOD:

Cross-sectional, region-wide, population-based serosurvey study in 88 randomly selected primary care centers of the Valencian Community.

RESULTS:

Seroprevalence of anti-nucleocapsid (indicative of past infection) and total receptor binding domain (indicative of past infection or vaccination) antibodies was 71.0% (confidence interval [CI] 67.8-74.2) and 98.4% (CI 97.5-99.3), respectively. 66.7% (CI 63.4-70.0) of the population shows hybrid immunity, but only 43.2% in those 80 and over.

CONCLUSIONS:

The high proportion of hybrid immunity detected is relevant for public health strategies. A second vaccination booster was advisable in the elderly population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: Europa Idioma: En Revista: Gac Sanit Assunto da revista: SAUDE PUBLICA Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: Europa Idioma: En Revista: Gac Sanit Assunto da revista: SAUDE PUBLICA Ano de publicação: 2023 Tipo de documento: Article